logo.jpg
Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress
22 mai 2023 08h05 HE | Processa Pharmaceuticals, Inc.
Company also to provide a corporate overview in a separate session HANOVER, MD, May 22, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a...
logo.jpg
Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative
18 mai 2023 08h00 HE | Processa Pharmaceuticals, Inc.
HANOVER, MD, May 18, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”) today announces it has received guidance from the U.S. Food and Drug...